• Record 1H FY26 revenue of $60.7m, up 13% vs pcp
• EBITDA of $7.8m, up 35% vs pcp
• Positive operating cash flow of $2.5m

SomnoMed Ltd, the global leader in oral appliance therapy for sleep apnea, has reported strong 1H FY26 results. The company achieved record 1H FY26 revenue of $60.7m, up 13% compared to the prior comparative period (pcp). This was driven by continued strong growth across Europe and North America. EBITDA increased by 35% to $7.8m, with the EBITDA margin improving from 11% in 1H FY25 to 13% in 1H FY26. The company generated positive operating cash flow of $2.5m, though free cash flow was negative ($0.9m) due to budgeted investments in manufacturing and R&D. SomnoMed also strengthened its senior leadership team with the appointment of a new Chief Marketing Officer and a newly created Chief Transformation Officer role. The company made progress on its Rest Assure product, with FDA clearance for the oral device and software platform, and is evaluating options to accelerate commercialization. For FY26, SomnoMed has reaffirmed guidance for revenue of $119m-$126m and EBITDA of $10m-$12m.

For FY26, SomnoMed has reaffirmed guidance for revenue of $119m-$126m and EBITDA of $10m-$12m, excluding lease payments, share/option expenses, unrealized foreign exchange gains/losses, one-off costs, and discontinued operations.

SomnoMed is focused on execution and delivery in FY26, with priorities including building a high-performing team and culture, generating earnings growth and positive operating cash flow, increasing manufacturing capacity, and improving customer turnaround times. The company is also progressing its Rest Assure product, with plans for sustainable growth and investment in FY27 and beyond.